Aarti Sathyanarayana, Rima El Atrache, M. Jackson, Sarah Cantley, Latania Reece, Claire Ufongene, T. Loddenkemper, K. Mandl, W. Bosl
{"title":"Measuring Real-Time Medication Effects From Electroencephalography.","authors":"Aarti Sathyanarayana, Rima El Atrache, M. Jackson, Sarah Cantley, Latania Reece, Claire Ufongene, T. Loddenkemper, K. Mandl, W. Bosl","doi":"10.1097/WNP.0000000000000946","DOIUrl":null,"url":null,"abstract":"PURPOSE\nEvaluating the effects of antiseizure medication (ASM) on patients with epilepsy remains a slow and challenging process. Quantifiable noninvasive markers that are measurable in real-time and provide objective and useful information could guide clinical decision-making. We examined whether the effect of ASM on patients with epilepsy can be quantitatively measured in real-time from EEGs.\n\n\nMETHODS\nThis retrospective analysis was conducted on 67 patients in the long-term monitoring unit at Boston Children's Hospital. Two 30-second EEG segments were selected from each patient premedication and postmedication weaning for analysis. Nonlinear measures including entropy and recurrence quantitative analysis values were computed for each segment and compared before and after medication weaning.\n\n\nRESULTS\nOur study found that ASM effects on the brain were measurable by nonlinear recurrence quantitative analysis on EEGs. Highly significant differences (P < 1e-11) were found in several nonlinear measures within the seizure zone in response to antiseizure medication. Moreover, the size of the medication effect correlated with a patient's seizure frequency, seizure localization, number of medications, and reported seizure frequency reduction on medication.\n\n\nCONCLUSIONS\nOur findings show the promise of digital biomarkers to measure medication effects and epileptogenicity.","PeriodicalId":117726,"journal":{"name":"Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society","volume":"167 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/WNP.0000000000000946","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
PURPOSE
Evaluating the effects of antiseizure medication (ASM) on patients with epilepsy remains a slow and challenging process. Quantifiable noninvasive markers that are measurable in real-time and provide objective and useful information could guide clinical decision-making. We examined whether the effect of ASM on patients with epilepsy can be quantitatively measured in real-time from EEGs.
METHODS
This retrospective analysis was conducted on 67 patients in the long-term monitoring unit at Boston Children's Hospital. Two 30-second EEG segments were selected from each patient premedication and postmedication weaning for analysis. Nonlinear measures including entropy and recurrence quantitative analysis values were computed for each segment and compared before and after medication weaning.
RESULTS
Our study found that ASM effects on the brain were measurable by nonlinear recurrence quantitative analysis on EEGs. Highly significant differences (P < 1e-11) were found in several nonlinear measures within the seizure zone in response to antiseizure medication. Moreover, the size of the medication effect correlated with a patient's seizure frequency, seizure localization, number of medications, and reported seizure frequency reduction on medication.
CONCLUSIONS
Our findings show the promise of digital biomarkers to measure medication effects and epileptogenicity.